T
Thomas W. Doebber
Researcher at Merck & Co.
Publications - 54
Citations - 9374
Thomas W. Doebber is an academic researcher from Merck & Co.. The author has contributed to research in topics: Peroxisome proliferator-activated receptor & Agonist. The author has an hindex of 33, co-authored 54 publications receiving 8893 citations.
Papers
More filters
Journal ArticleDOI
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou,Robert W. Myers,Ying Li,Yuli Chen,Xiaolan Shen,Judy Fenyk-Melody,Margaret Wu,John Ventre,Thomas W. Doebber,Nobuharu Fujii,Nicolas Musi,Michael F. Hirshman,Laurie J. Goodyear,David E. Moller +13 more
TL;DR: It is reported that metformin activates AMPK in hepatocytes; as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed.
Journal ArticleDOI
Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects
Joel Berger,Mark D. Leibowitz,Thomas W. Doebber,Alex Elbrecht,Bei Zhang,Gaochou Zhou,Chhabi Biswas,Catherine A. Cullinan,Nancy S. Hayes,Ying Li,Michael R. Tanen,John Ventre,Margaret Wu,Gregory D. Berger,Ralph T. Mosley,Robert W. Marquis,Conrad Santini,Soumya P. Sahoo,Richard L. Tolman,Roy G. Smith,David E. Moller +20 more
TL;DR: Novel, non-thiazolidinedione agonists for PPARγ and PPARδ that were identified by radioligand binding assays improve hyperglycemia and hypertriglyceridemia in vivo and are able to potentiate preadipocyte differentiation.
Journal ArticleDOI
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
Joel Berger,Ann Petro,Karen L. MacNaul,Linda J. Kelly,Bei B. Zhang,Karen Richards,Alex Elbrecht,Bruce A. Johnson,Gaochao Zhou,Thomas W. Doebber,Chhabi Biswas,Mona Parikh,Neelam Sharma,Michael R. Tanen,G. Marie Thompson,John Ventre,Alan D. Adams,Ralph T. Mosley,Richard S. Surwit,David E. Moller +19 more
TL;DR: It is established that novel selective PPARgamma modulators can produce altered receptor conformational stability leading to distinctive gene expression profiles, reduced adipogenic cellular effects, and potentially improved in vivo biological responses.
Journal ArticleDOI
Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1
Guoqiang Jiang,Zhihua Li,Franklin Liu,Kenneth P. Ellsworth,Qing Dallas-Yang,Margaret Wu,John Ronan,Christine Esau,Cain Murphy,Deborah Szalkowski,Raynald Bergeron,Thomas W. Doebber,Bei B. Zhang +12 more
TL;DR: Prevention of diet-induced obesity with concomitant reductions in SCD1 expression and the ratio of oleate to stearoyl-CoA in tissues and plasma and pharmacological inhibition ofSCD1 represents a new target for the treatment of obesity and related metabolic disorders.
Journal ArticleDOI
Targeted Disruption of the Tumor Necrosis Factor-α Gene: Metabolic Consequences in Obese and Nonobese Mice
John Ventre,Thomas W. Doebber,Margaret Wu,Karen L. MacNaul,Karla Stevens,Manolis Pasparakis,George Kollias,David E. Moller +7 more
TL;DR: It is concluded that T NF-α functions to regulate plasma triglycerides and body adiposity and that although TNF-α contributes to reduced insulin sensitivity in older or obese mice, the absence of TNF -α is not sufficient to substantially protect against insulin resistance in the GTG hyperphagic model of rodent obesity.